In¯ammatory breast cancer (IBC) is an aggressive form of breast cancer with a 5-year disease-free survival of less than 45%. Little is known about the genetic alterations that result in IBC. In our previous work, we found that WISP3 was speci®cally lost in human IBC tumors when compared to stage-matched, non-IBC tumors. We hypothesize that WISP3 has tumor suppressor function in the breast and that it may be a key genetic alteration that contributes to the unique IBC phenotype. The full-length WISP3 cDNA was sequenced and cloned into an expression vector. The resulting construct was introduced in to the SUM149 cell line that was derived from a patient with IBC and lacks WISP3 expression. In soft agar, stable WISP3 transfectants formed signi®cantly fewer colonies than the controls. Stable WISP3 transfectants lost their ability to invade and had reduced angiogenic potential. WISP3 transfection was eective in suppressing in vivo tumor growth in nude mice. Mice bearing WISP3 expressing tumors had a signi®cantly longer survival than those with vectorcontrol transfectant tumors. Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis.
Introduction
In¯ammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer and accounts for approximately 6% of new breast cancer cases annually in the United States (Jaiyesimi et al., 1992; Lee, 1924) . It is also a very distinct clinical and pathological form of breast carcinoma. It is characterized clinically by erythema, skin nodules, dimpling of the skin (termed`peau d'orange') and by a rapid onset of disease, typically progressing within 6 months (Jaiyesimi et al., 1992; Lee, 1924; Merajver et al., 1997; Swain et al., 1987) . Pathologically, carcinomatous tumor emboli spread through the dermal lymphatics which are responsible for the clinical signs and symptoms (Lee, 1924) . IBC is generally not associated with precursor lesions (Jaiyesimi et al., 1992; Lee, 1924) . From the outset, IBC is highly invasive and it appears to be capable of metastases from its inception. It is estimated that nearly all women with IBC have nodal involvement at the time of diagnosis, and over one-third have distant metastases (Merajver et al., 1997; Swain et al., 1987) . In spite of new advances in breast cancer therapy, the overall 5-year disease-free survival rate is less than 45% (Merajver et al., 1997; Swain et al., 1987) .
The genetic alterations underlying the development and progression of IBC were unknown until recently. Our laboratory identi®ed two genes that are consistently and concordantly altered in human IBC when compared to stage-matched, non-IBC tumors: loss of WISP3 and over-expression of RhoC-GTPase (van Golen et al., 1999) .
WISP3 has been identi®ed as a member of the CCN family of proteins, which have important biological functions in normal physiology as well as in carcinogenesis (Perbal, 2001 ). There are only two publications in the literature on the biological eects of WISP3 and very little is known about the expression pattern and function of this novel gene (Hurvitz et al., 1999; Pennica et al., 1998) . We hypothesize that WISP3 may function as a growth-suppressing factor in breast carcinogenesis and that it may be a key genetic alteration in IBC in particular. To test this hypothesis, we set out to determine whether restoring WISP3 expression in an IBC cell line, SUM149, could abrogate or modulate the highly malignant IBC phenotype. We observed that stably transfected SUM149/WISP3 cells exhibited a striking decrease in proliferation rate, anchorage independent growth, invasion, and tumor growth in nude mice compared to empty vector transfectants. This work suggests new insights into the role of WISP3 in carcinogenesis in general.
Results
Transfection with the SUM149 cell line with WISP3 cDNA Figure 1 shows the Western blot analysis of WISP3 protein in whole cell lysates from four clones of SUM149/ WISP3 stable transfectants, SUM149/Flag (transfection controls), SUM149 wild type, and HME cells (human mammary epithelial cells). We used a speci®c anti-WISP3 antibody (gift from Dr Mathew Warman).
Statistically signi®cant dierences were found when each SUM149/WISP3 clone was compared to the SUM149/Flag control (P50.04, t-test).
WISP3 induces a striking morphologic change in IBC cell line
After stable transfection with WISP3 cDNA, we observed marked morphologic dierences between the SUM149/WISP3 clones and SUM149/Flag control ( Figure 2a ). Whereas the control SUM149/Flag cells had a characteristic tightly packed, cobblestone appearance, with a cuboidal shape and high nuclear to cytoplasmic ratio, the SUM149/WISP3 transfectants were heterogeneous in size and morphology. They became large, round, and¯at with abundant granular and vacuolated cytoplasm and ill-de®ned cell borders. A detailed ultrastructural analysis by electron microscopy demonstrate that the WISP3 transfectants exhibited numerous cytoplasmic lysosomal bodies surrounded by a membrane, some containing electron-dense material and invaginated and convoluted nuclei (Figure 2b ). These morphologic features have been described in cells undergoing senescence (Romanov et al., 2001; Tsugu et al., 2000) .
WISP3 partially abrogates angiogenesis in IBC
As illustrated in Figure 3a , SUM149/WISP3 clones produce signi®cantly decreased levels of FGF2 (bFGF) and VEGF, key pro-angiogenic factors. The levels of IL-6, another pro-angiogenic cytokine were signi®-cantly decreased. To investigate whether the decreased production of angiogenic factors induced by restoration of WISP3 expression resulted in the inhibition of neovascularization, we carried out rat aortic ring assays. After 10 days of incubating a rat aortic ring with a 106 concentration of the cell culture supernatant, fewer vessels were formed by SUM149/WISP3 cells when compared to the controls (Figure 3b) Expression of WISP3 reduces the proliferation rate, anchorage-independent growth, and the invasive ability of IBC cells
As anchorage independent growth is a hallmark of malignant transformation, we investigated whether expression of WISP3 in highly malignant SUM149 cell line abolished this feature. After 14 days of growth in soft agar four WISP3 expressing clones formed signi®cantly fewer and smaller colonies than the control cells (P50.05), (Figure 4a,b) . Figure 4c shows the results of the MTT assay and illustrates that the proliferation rate of three dierent clones of SUM149 cells transfected with WISP3 decreased signi®cantly when compared to controls (P50.05). The ability of the transfectants to invade and intravasate was studied using the sea urchin extracellular membrane (SU-ECM) invasion assay. This assay provides a naturally serum-free, selectively permeable basement membrane that closely mimics the type of extracellular matrix that cells encounter in vivo. Mean invasion percentages were calculated from three independent analyses of 50±100 random cells. We found that transfection with WISP3 cDNA completely abolished the ability of IBC cells to invade, compared to the control (the mean+s.d. for invasion of SUM149/¯ag cells was 14+3, when compared to 0 for both clones of SUM149/WISP3).
WISP3 expression inhibits cellular growth by inducing accumulation of p27 kip1 and p21 waf1 in cancer cells and induces apoptosis
Based on the morphologic changes induced by transfection with WISP3, we set out to investigate whether WISP3 caused alterations in the regulation of the cell cycle, that could in turn be contributing to the inhibition of cellular proliferation, anchorage-independent growth, and in vivo tumor growth. To elucidate the possible eect of WISP3 on the cell cycle regulators, the round and vacuolated cells (SUM149/ WISP3) were assayed for the presence of several key cell cycle regulators by Western immunoblots. Interestingly, when compared to the control cells, the level of p27 kip1 and p21 waf1 were increased in the WISP3 transfectants when compared top SUM149/¯ag control cells (P=0.0003 and P=0.003 for p27 kip1 expression for clones 1 and 2 respectively, and P=0.001 and P=0.06 for p21 waf1 expression for clones 1 and 2 respectively, t-test, Figure 5 ). Concordantly, SUM149/ WISP3 cells exhibited decreased levels of cyclin E and PCNA, a reliable marker for cellular proliferation, when compared to the SUM149/¯ag control cells (P=0.02 and P=0.02 for cyclin E expression for clones 1 and 2 respectively, and P=0.0003 and P=0.003 for PCNA expression for clones 1 and 2 respectively, t-test, Figure 5 ).
We noticed an increased percentage of apoptotic cells after stable transfection with WISP3 detected by the Annexin V assay by¯ow cytometry. SUM149/ WISP3 transfectants had 30% apoptotic cells when compared to SUM149/Flag control cell line with only 13% apoptotic cells.
WISP3 inhibits in vivo tumor growth and improves survival of mice
Given that WISP3 aects cell cycle regulation, proliferation rates and anchorage independent growth, we investigated the eect of restoration of WISP3 expression on SUM149 xenograft tumor growth and survival of the host mice. Three groups of 10±11 mice were injected with two clones of SUM149/WISP3 stable transfectants and a control group (SUM149/ Flag and SUM149 wild-type, ®ve mice each). Mice with orthotopically implanted tumor cells were monitored weekly for tumor formation over an 8-week period. By the 8th and ®nal week of the experiment, palpable tumors developed in 20 of the 21 mice that received injection of the SUM149/WISP3 clones and in nine out of 10 mice given injection of control clones (®ve injected with SUM149/Flag and ®ve injected with wild-type SUM149). The rate of tumor formation between WISP3 transfectants and controls diered (Table 1) . Speci®cally, the clones transfected with WISP3 formed tumors at a slower rate than the controls (logistic regression analysis adjusted for longitudinal correlation, P=0.05). Moreover, when tumor volume was compared at each week (starting at week 2), it was signi®cantly lower in the tumors formed by SUM149/WISP3 transfectants than in the tumors formed by the controls (P=0.05). When the slopes of the regression lines were compared, striking dierences were found between the WISP3 transfectants and control cells (P50.001, Figure 6a ,b). At week 5, two tumors from each clone and from the control were excised. WISP3 mRNA expression was con®rmed by quantitative RT±PCR. Levels of WISP3 expression were found to be similar to those of preinjection. Taken together, these results demonstrate that tumors formed by SUM149/WISP3 take longer to grow and are smaller than controls.
To address whether the tumors formed by the transfectants expressing WISP3 were pathologically dierent from the control, histopathologic study of the tumors was carried out. As shown in Figure 6c , SUM149/Flag tumors were highly anaplastic, had Figure 5 Western immunoblot of cell culture media of control (SUM149/FLAG), and two WISP3 expressing clones using antibodies for p27kip1, p21waf1/cip1, cyclin E, and PCNA Table 1 Rate of tumor formation after orthotopic injection in the mammary fat pad of SUM149 wild-type, SUM149/Flag, and two stable clones of SUM149/WISP3 transfectants in female athymic nude mice. Tumors formed by the WISP transfectants took a longer time to develop than tumors formed by the control cells (P=0.05, logistic regression analaysis)
2 weeks 4 weeks 6 weeks 8 weeks n (%) n (%) n (%) n (%) (100) strikingly atypical cells forming solid aggregates, with no glandular formation, a sign of poor dierentiation, and extensive areas of necrosis. The cells exhibited high mitotic activity (mean 88 mitoses per 10 high power ®eld (4006)) and numerous abnormal mitoses. In contrast, the tumors derived from SUM149/WISP3 clones had less nuclear pleomorphism and slightly better dierentiation evidenced by occasional gland formation. These tumors had less necrosis and the mitotic activity was greatly decreased (mean 11 mitoses per 10 high power ®elds).
Discussion
WISP3 is located in chromosome 6q21±22 and encodes for a 354 amino acid, 39 292 Da protein with the modular architecture of the CCN family of proteins which includes connective tissue growth factor (CTGF), Cyr61, Nov, WISP1 and WISP2 (Babic et al., 1998; Hashimoto et al., 1998; Hurvitz et al., 1999; Kireeva et al., 1996; O'Brien and Lau, 1992, Pennica et al., 1998; Perbal, 2001; Wong et al., 1997; Xu et al., 2000) . The CCN proteins participate in fundamental biological processes such as cell proliferation, migration, wound healing, angiogenesis and tumorigenesis (Perbal, 2001) . They have a range of biological properties that might be dependent upon the cellular context (Perbal, 2001) .
In tumorigenesis, Cyr61 and WISP1 were reported to act as positive regulators of cell growth (Babic et al., 1998; Hashimoto et al., 1998; Kireeva et al., 1996; O'Brien and Lau, 1992; Pennica et al., 1998; Wong et al., 1997; Xu et al., 2000) ; Nov expression was found to correlate with the development of metastases in Ewing's sarcomas, prostate cancer, and renal cell carcinomas (Perbal, 2001) , whereas it was found to act as a negative growth regulator of glioblastoma cell lines (Li et al., 1996) . Furthermore, in primary human colonic adenocarcinomas, the expression of WISP2 was signi®cantly decreased compared to normal colon (Pennica et al., 1998) , and it was not detected in the epithelial tumor cells of mammary carcinoma obtained from Wnt-1 transgenic mice (Pennica et al., 1998) . Similarly, in our study we could not detect WISP3 mRNA expression in 80% of the IBC human tissues studied (van Golen et al., 1999) . The expression of ELM1/WISP1, which had been reported to suppress the metastatic potential of murine melanoma cells (Hashimoto et al., 1998) , was signi®cantly increased in most human colonic carcinomas (Pennica et al., 1998; Xu et al., 2000) . These data provide compelling evidence that the CCN proteins may have opposing functions in carcinogenesis in dierent cell types and tissues.
There are only two previous publications in the literature on the biologic properties of WISP3 (Hurvitz et al., 1999; Pennica et al., 1998) . In one of these studies, the WISP3 gene was signi®cantly overexpressed in human colon carcinoma (Pennica et al., 1998) whereas Hurvitz et al. (1999) found loss of function mutations in the WISP3 gene to be associated with progressive pseudorheumatoid dysplasia in humans (Hurvitz et al., 1999) . Patients with progressive pseudorheumatoid dysplasia due to WISP3 loss-offunction mutations have not been reported to have higher rates of cancer; however this has not been systematically sought in this cohort (Hurvitz et al., 1999) . Our data provide evidence that WISP3 has tumor suppressor function in the mammary gland.
Using a modi®ed version of the dierential display technique and in situ hybridization of human breast cancer tissues, we found that WISP3 is lost in 80% of IBC and in 21% of stage matched, non IBC tumors (P=0.0013, Fisher's exact test) (van Golen et al., 1999) . WISP3 loss was found in concert with RhoCGTPase over-expression in 90% of archival IBC patient samples, but not in stage-matched non-IBC tumors (van Golen et al., 1999) . Our laboratory demonstrated that RhoC-GTPase over-expression produces a motile and invasive phenotype in human mammary epithelial cells, primarily through formation of actin stress ®bers and focal adhesion points (van Golen et al., 2000b) . We hypothesized that loss of expression of WISP3 contributes to the development of the IBC phenotype by altering angiogenesis and tumor growth, therefore complementing the role of RhoCGTPase over-expression.
One of the features that de®ne the IBC phenotype as unique is its rapid progression, with fast growth and invasion, making it the most lethal form of locally advanced breast cancer (Jaiyesimi et al., 1992; Lee, 1924; Merajver et al., 1997; Swain et al., 1987) . IBC is characterized by a rapid onset of disease, typically arising within 6 months, and by the time of diagnosis, the majority of patients have locoregional and distant metastatic disease (Jaiyesimi et al., 1992; Lee, 1924; Merajver et al., 1997; Swain et al., 1987) . Transfection of the IBC cell line SUM149 with WISP3 cDNA inhibited some of these key phenotypic characteristics.
The proliferation rate of highly aggressive SUM149 cell line was decreased, and growth under anchorage independent conditions was greatly reduced in the stable WISP3 transfectants. In comparison with the control cells, the WISP3 transfectants produced 6±16-fold less colonies than the control cells. Similarly, the eect of transfection with WISP3 in cancer cell invasion was striking. Using the sea urchin invasion assay, a system that closely resembles the extracellular matrix that cells encounter in vivo, the WISP3 transfectants did not invade, when compared to controls. Furthermore, transfection with WISP3 cDNA greatly reduced tumor growth in vivo. Interestingly, transfection with WISP3 also resulted in a decrease in the rate of tumor uptake.
Another feature that makes IBC unique is its high angiogenic and angioinvasive potential. We proved that WISP3 suppressed pathologic neovascularization by reducing the levels of key pro-angiogenic factors, FGF2, VEGF, and IL-6.
Although the mechanism of action of the CCN proteins in general and of WISP3 in particular has not been elucidated, there are several candidates. The ®rst of these could be by regulating nuclear cycling and/or apoptotic functions (Lopez-Bermejo et al., 2000; Sprenger et al., 1999) . We observed a marked morphologic change in the SUM149 cell line after transfection with WISP3 cDNA. Histopathologic study of the tumors developed in nude mice revealed that those derived from the WISP3 transfectants had a signi®cant reduction in the mitotic activity, as well as better dierentiation and less cellular and nuclear pleomorphism. To better understand these morphologic changes, we studied the levels of key cell cycle regulators and apoptosis. The levels of the cell cycle inhibitors p27 kip1 and p21 waf1 were markedly increased by WISP3 expression, and cyclin E was concordantly decreased. Consistent with these cell-cycle speci®c gene expression changes, the percentage of apoptotic cells was also increased in the WISP3 transfectants. These data suggest that in the mammary gland, WISP3 expression may inhibit cancer cell growth through modulation of the cell-cycle regulation and apoptosis.
A second possible mode of tumor suppression activity for WISP3 is by regulating angiogenesis (Babic et al., 1998; Perbal, 2001) . As the tumor grows, it requires and promotes an increase in neovascularization. This activation of the angiogenic switch involves the up-regulation of angiogenic inducers and/or downregulation of angiogenic inhibitors. Our results show that WISP3 expression induces a reduction in the level of key pro-angiogenic factors which results in a decrease in functional neovascularization.
A third mechanism of WISP3 tumor suppression could be by binding IGF-like ligands. WISP3 has the modular architecture of the CCN proteins and consists of four domains: an IGF-binding protein domain, a Von Willebrand factor domain, a thrombospondin 1 domain, and a C terminal domain (Babic et al., 1998; Hashimoto et al., 1998; Hurvitz et al., 1999; Pennica et al., 1998; Perbal, 2001) . The N-terminal domain includes the ®rst 12 cysteine residues and contains the highly conserved IGF binding consensus sequence (GCGCCXXC) which provides the proper folding of the protein to bind IGF (Byun et al., 2001; Kim et al., 1997; Oh et al., 1996) . Although this sequence is believed to be required for IGF-binding, the actual binding site may be slightly downstream of it (Imai et al., 2000; Kalus et al., 1998) . The thrombospondin type 1 domain (TSP1) is presumably involved in inhibition of angiogenesis (Perbal, 2001) . The carboxy-terminal domain (CT) is present in most CCN proteins described to date and forms a cysteine knot. The protein is folded into two highly twisted antiparallel pairs of beta-strands and contains three disul®de bonds that may participate in dimerization and receptor binding. The CT domain does not appear to be as critical in IGF binding as the N-terminal region that contains the IGF-binding protein motif (Imai et al., 2000; Kalus et al., 1998) . Although WISP3 may function in tumorigenesis through modulation of IGF binding, this is less likely since IGF-binding activity could not be demonstrated for other members of the CCN family (Perbal, 2001) . We are currently investigating this possibility in mammary tissue.
In summary, we have proven that restoring expression of WISP3 into an aggressive IBC cell line, SUM149, inhibited cellular proliferation, drastically decreased angiogenesis, inhibited invasion, and decreased anchorage-independent growth, all hallmarks of malignant transformation. Restoration of WISP3 expression resulted in a morphologic alteration and induced tumor cell apoptosis with concordant molecular changes in cell cycle speci®c gene, p27 kip1 and p21 waf1 . Finally, when SUM149 cells transfected with WISP3 were injected into female athymic nude mice, the rate of tumor formation and the tumor volume were markedly decreased when compared to controls. These studies demonstrate for the ®rst time that WISP3 has strong tumor suppressor function in the mammary gland. Given the seemingly speci®c role that WISP3 plays in the development of IBC, our work may lead to the development of novel therapies that replace or mimic WISP3 function to treat this particularly challenging form of breast cancer.
Materials and methods

Cell culture
The derivation of SUM149 cell line has been described previously by Ethier et al. (1993) . This cell line was developed from a human primary in¯ammatory breast cancer and has lost WISP3 expression (Figure 1, lane F) . Cells were cultured in Ham's F-12 medium supplemented with 5% FBS, hydrocortisone (1 mg/ml), insulin (5 mg/ml), fungizone (2.5 mg/ml), Gentamycin (5 mg/ml) and each of Penicillin/ streptomycin (100 m/ml) at 37G under 10% CO 2 .
Construction of expression vector and stable transfection
Total RNAs were isolated from human mammary epithelial cells (HME) using a Trizol kit (Life Technologies, Inc., Gaithersburg, MD, USA). First-strand cDNA synthesis was performed using 1 mg of total RNA with AMV reverse transcriptase (Promega, Madison, WI, USA) and oligo (dT) as a primer. Two ml of the reaction mixture were used for PCR ampli®cation. Human WISP3 cDNA was ampli®ed by PCR using the following forward and reverse primers: 5'-ATGCAGGGGCTCCTCTTCTGC-3' and 5'-ACTTTTCCC-CCATTTGCTTG-3', under the following conditions: denaturing for 1 min at 948C, annealing for 1 min at 588C, and elongation for 2 min at 728C for 35 cycles. The PCR product was cloned into pGEM-T Easy vector (Promega, Madison, WI, USA). The 1.1 kb full-length cDNA encoding WISP3 was excised by EcoRI and subcloned into the EcoRI site of pFLAG-CV4 vector (Sigma, Saint Louis, MO, USA). The insert was con®rmed by DNA sequencing. The plasmids were puri®ed. Subsequently, the SUM149 cells were transfected with pFLAG-WISP3 and pFlag control vector by FuGene TM 6 transfection reagent (Roch-Boehringer Mannheim, Mannheim, Germany), and selected in the medium containing 150 mg/ml G418. The cells surviving during selection were expanded and maintained in the selected medium.
Western immunoblots
Western immunoblots were performed using the following primary antibodies: WISP3 polyclonal antibody (gift from Dr Matthew Warman), p27 kip1 , p21 waf1 , PCNA (Zymed, San Francisco, CA, USA) cyclin E (SC-247, Santa Cruz, CA, USA), cyclin D1 (SC-246, Santa Cruz, CA, USA), and actin (Sigma Chemical Co.). Cells were lysed in RIPA buer (16 PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml PMSF, 1 mM sodium orthovanadate, and 0.3 mg/ml aprotinin; Sigma Chemical Co.). Whole cell lysates (50 mg) were boiled in Laemelli buer for 5 min, separated by 10% SDS±PAGE and transferred to PVDF membrane. Nonspeci®c binding was blocked by incubation with 1.5% BSA in Tris-buered saline with 0.5% Tween-20 (Sigma Chemical Co.). Antibody-antigen complexes were detected with an enhanced chemiluminescence kit (ECL, Amersham, Arlington Height, IL, USA) following the manufacturer's instructions.
Anchorage-independent growth
Cells from four SUM149/WISP3 stable clones and controls were seeded at a density of 1610 3 per 35-mm plated in 0.3% agar and Ham's F-12 supplemented with 10% FBS, and plated on a base of 0.6% agar, Ham's F-12 and 10% FBS. Each assay was performed in triplicate. Plates were maintained at 378C under 10% CO 2 for 3 weeks. Colonies greater than or equal to 100 mm in diameter were counted.
Annexin V-FITC binding assay
This assay was performed using the Apo Alert Annexin V kit (Clontech, CA, USA). Three clones of stably transfected SUM149/WISP3 and SUM149/Flag control cells (1610   6   ) were trypsinized, washed and incubated in binding buer (16) containing 1 mg/ml of Annexin V-FITC conjugate (Clontech, CA, USA) for 10 min in the dark. Cells were next stained with propidium iodide (20 mg/ml) and analysed by¯ow cytometry (Martin et al., 1995) .
Monolayer growth rate
Monolayer culture growth rate was determined by qualitative measurement of the conversion of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma Chemical Co.) to a water insoluble formazan by viable cells. Three thousand cells in 200 ml of culture medium were plated in 96-well plates and grown under normal conditions. Cultures were assayed at 0, 1, 3, 4 and 5 days by the addition of MTT and incubation for 1 h at 378C. The MTT containing medium was aspirated and 100 ml DMSO (Sigma Chemical Co.) was added to lyse the cells and solubilize the formazan. Absorbance values of the lysates were determined on a Dynatech MR 5000 microplate reader at 540 nm.
Invasion and intrainvasion
To study invasion, the sea urchin extracellular membrane (SU-ECM) invasion assay was used (Livant et al., 1995) . Cells were layered onto sea urchin embryo extracellular basement membrane and allowed to invade for 4 h. The cells on the SU-ECM were ®xed using paraformaldehyde and visualized under a microscope. Mean invasion percentages were calculated from two independent analyses of 50±100 randomly chosen cells in contact with the surfaces of the basement membranes.
Angiogenesis and angiogenic factor analysis
To study whether WISP3 modulated the angiogenic activity of IBC, the levels of key pro-angiogenic factors known to be secreted by IBC (VEGF, FGF2, were measured in the cell supernatants by ELISA (van Golen et al., 2000a) . A functional analysis of angiogenesis of the conditioned media was performed. We used the rat aortic assay in which we assessed the amount of new blood vessel growth elicited by the conditioned medium of the WISP3 transfected cells (Nissanov et al., 1995) . Approximately 1-mm thick rings were cut from the aorta of a freshly sacri®ced rat and embedded into Matrigel in the center of a 35-mm dish. Vessel outgrowth from the aorta into the Matrigel was visually quanti®ed by counting the branching points in six randomly chosen ®elds for the SUM149/WISP3 and control SUM149/¯ag cells under a light microscope and compared at 7 and 10 days after planting. Statistical analysis was performed using the t-test.
In vivo tumor formation
Groups of 5±11, 10-week old, nude, athymic female mice were orthotopically injected into the mammary fat pad with 2610 6 cells. Each group was injected with either a control (SUM149/Flag, or wild-type SUM149) clone, or one of two WISP3-expressing clones. The clones were selected according to their anchorage-independent growth characteristics. Mice were then monitored weekly for tumor formation for 8 weeks and for signs of wasting and chachexia as surrogates of survival for 18 weeks. If tumors were present, tumor volume was calculated using the formula (16w 2 )/2 (where 1=length and w=width of tumor). Rates of tumor formation were analysed by the Kruskal-Wallis method; and tumor volumes were assessed between the groups by the Mann±Whitney Utest. After the mice developed signs and symptoms of chachexia, they were sacri®ced and their tumors were removed. A portion of each tumor (1/3) was digested with 0.1% collagenase (Type I) and 50 mg/ml DNase (Worthington Biochemical Corp. Freehold, NJ, USA), and RNA was collected for RT±PCR analysis. The remainder of the tumor tissues were used for histopathological study. After removal of the tumors, part of the tissues were ®xed in 10% buered formalin and processed for histopathological evaluation by paran-embedding and hematoxylin and eosin staining. Histological features studied included degree of anaplasia, mitotic activity, presence and amount of necrosis, and degree of dierentiation (e.g. glandular formation).
